2031153-61-2
2031153-61-2 structure
- Name: Iscalimab
- Chemical Name: Iscalimab
- CAS Number: 2031153-61-2
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2023-02-19 14:25:58
- Modify Date: 2025-08-26 18:39:15
-
Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases[1][2][3].
| Name | Iscalimab |
|---|
| Description | Iscalimab (CFZ-533) is a non-depleting IGg1 monoclonal antibody targeting CD40 (KD: 0.3 nM). Iscalimab can be used for research of Graves' hyperthyroidism and autoimmune diseases[1][2][3]. |
|---|---|
| Related Catalog | |
| Target |
CD40:0.3 nM (IC50) |
| In Vitro | Iscalimab (0.01-1 μg/mL，过夜) 抑制 rCD154 诱导的原代单核细胞衍生树突状细胞 (moDC) 产生 TNF，IC50 为 0.04 μg/mL[3]。 Iscalimab (3 天) 抑制 rCD154 诱导的人、恒河猴和食蟹猴 PBMC 增殖，IC50 分别为 0.02、0.03 和 0.01 μg/mL[3]。 Iscalimab 结合来自人、恒河猴和食蟹猴的 B 细胞上的 CD40，EC50 值约为 0.2 μg/mL[3]。 Iscalimab (2 μg/mL, 3 h) 以 CD40 依赖性方式被 B 细胞内化[3]。 Cell Viability Assay[3] Cell Line: PBMCs from humans, rhesus and cynomolgus animals Concentration: 0-1 μg/mL approximately Incubation Time: 3 days Result: Inhibited rCD154-induced proliferation of PBMCs with IC50s of 0.02, 0.03, and 0.01 μg/mL, respectively. |
| In Vivo | Iscalimab (150 mg/kg/周，皮下注射，持续 13 周) 耐受性良好，不会对恒河猴造成任何剂量限制性毒性[3]。 Iscalimab (10 mg/kg，静脉注射) 完全抑制恒河猴的 T 细胞依赖性抗体反应[3]。 Iscalimab (30 mg/kg，静脉内) 可延长肾移植食蟹猴的同种异体移植物存活期[4]。 Animal Model: Kidney transplant cynomolgus[4] Dosage: 30 mg/kg Administration: i.v. Result: Prolonged allograft survival. Well-tolerated with no evidence of thromboembolic events or CD40 pathway activation. |
| References |
| No Any Chemical & Physical Properties |